Mergers & AcquisitionsMediumUpdated•Originally published 22 October 2026•Updated 22 October 2026•
1 min read
Gilead to Acquire PepStar’s HCXT-2001 Drug Program for $1.275 Billion
Key Facts
1Gilead has agreed to acquire PepStar’s inflammation drug program in a deal valued at $1.28 billion.
Gilead has agreed to acquire PepStar’s oral IL-23R inhibitor program in a cash deal valued at $1.275 billion. According to investing.com, the definitive agreement includes the purchase of the lead therapeutic asset HCXT-2001.
The acquisition aims to bolster Gilead's portfolio in the inflammation and immunology space, following recent clinical trial successes in related treatments. This strategic move reflects a broader trend of pharmaceutical entities expanding their pipelines through targeted asset acquisitions.